Exhibit 99.1

 

SCHEDULE A

 

Information regarding members of the investment committee of SV BCO I GP LLP:

 

Name

  

Residence or

Business

Address

  

Present principal

Occupation or

Employment;

Principal business

of Employer

  

Name of Employer

and Address where
Employment is
Conducted

  

Citizenship

                 
Michael Ross, Ph.D.   c/o SV Health Investors, 28 State Street, Suite 980, Boston, MA 02109  

Managing Partner;

International life

sciences venture capital investments

   SV Health Investors, 28 State Street, Suite 980, Boston, MA 02109   USA
         
Nikola Trbovic, Ph.D.   c/o SV Health Investors, 28 State Street, Suite 980, Boston, MA 02109  

Managing Partner;

International life

sciences venture capital investments

   SV Health Investors, 28 State Street, Suite 980, Boston, MA 02109   USA
                 
Catherine Bingham  

c/o SV Health Managers,

71 Kingsway, London, WC2B 6ST, UK

  

Managing Partner;

International life

sciences venture capital investments

  

SV Health Managers,

71 Kingsway, London, WC2B 6ST, UK

   UK
                 
Jamil Beg   c/o SV Health Investors, 28 State Street, Suite 980, Boston, MA 02109  

Partner;

International life

sciences venture capital investments

   SV Health Investors, 28 State Street, Suite 980, Boston, MA 02109   USA

 

 

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D, including all amendments thereto, with respect to the common stock, par value $0.0001 per share, of TRex Bio, Inc., and further agree that this Joint Filing Agreement shall be included as an exhibit to the first such joint filing and may, as required, be included as an exhibit to subsequent amendments thereto.

 

Each of the undersigned agrees and acknowledges that each party hereto is (i) individually eligible to use such Schedule 13D and (ii) responsible for the timely filing of such Schedule 13D and any and all amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein; provided that no party is responsible for the completeness and accuracy of the information concerning any other party unless such party knows or has reason to believe that such information is inaccurate.

 

This Joint Filing Agreement may be executed in any number of counterparts, all of which together shall constitute one and the same instrument. A facsimile, telecopy or other reproduction of this Joint Filing Agreement may be executed by one or more parties hereto, and an executed copy of this Joint Filing Agreement may be delivered by one or more parties hereto by facsimile or similar instantaneous electronic transmission device pursuant to which the signature of or on behalf of such party can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes as of the date hereof.

 

[signature page follows]

 

 

 

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of this 16th day of October, 2026.

 

  SV Biotech Crossover Opportunities Fund LP
  By: SV BCO I GP LLP, its General Partner
     
  /s/ James Costine
  Name: James Costine
  Title: Member

 

  SV BCO I GP LLP
     
  /s/ James Costine
  Name: James Costine
  Title: Member